NVAX - Novavax Biotech Short or not?
업데이트됨
NVAX as seen on the weekly chart has been in price distress for a long time.
It has only one product on the market due to various issues with the FDA process.
It has a variety of products in development as linked below.
The question is whether it will run out of cash before a sustained revenue
stream develops. FDA approvals for the pipeline products could take years
( the days of emergency approvals for COVID and related are over)
It would seem that a rich uncle like Moderna ( MRNA) would codcme
around with a take-over offer that could send shares into a moonshot
to back when NVAX thrived before its 95% price decline in the past two
years. This seems to be a great short swing play until more products come
to market or a take-over is announced. This is affirmed by the MACD
histogram being persistently negative for the long-term.
It has only one product on the market due to various issues with the FDA process.
It has a variety of products in development as linked below.
The question is whether it will run out of cash before a sustained revenue
stream develops. FDA approvals for the pipeline products could take years
( the days of emergency approvals for COVID and related are over)
It would seem that a rich uncle like Moderna ( MRNA) would codcme
around with a take-over offer that could send shares into a moonshot
to back when NVAX thrived before its 95% price decline in the past two
years. This seems to be a great short swing play until more products come
to market or a take-over is announced. This is affirmed by the MACD
histogram being persistently negative for the long-term.
노트
NVAX is finally climbing back up over 25% since April 1st. Call options for 5/19 are up over 100% adding into the trade now.
면책사항
이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.